Drug intelligence / Profile preview

Quadrivalent VLP Vaccine

Development stage: Phase 2
Lead developer: Novavax
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The quadrivalent VLP vaccine is a recombinant virus-like particle (VLP) vaccine candidate developed by Novavax for seasonal influenza. It is designed to present four different strains of influenza virus, each expressing strain-specific hemagglutinin (HA) and neuraminidase (NA) antigens. VLPs are non-infectious, mimicking the virus structure without containing genetic material, thereby stimulating an immune response without causing disease. The vaccine aims to evaluate its immunogenicity and safety in healthy adults.

Other names: Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant)Seasonal Influenza VLP

Targets

HA (Hemagglutinin)Neuraminidase

Beyond the preview

Go deeper on Quadrivalent VLP Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quadrivalent VLP Vaccine.

Explore the full profile